INNOVAX®-ND-IBD
As technology evolves, so does poultry disease protection. INNOVAX-ND-IBD provides life-long protection against infectious bursal disease, Newcastle disease and Marek’s disease in one easy-to-administer dose.
Advantages
Unique 3-in-1 protection
Life-long disease prevention
Early immune response
More efficient disease control
How It Works
INNOVAX-ND-IBD is administered in ovo or subcutaneously into day-old chicks at the hatchery to ensure the viability of this cell- associated vaccine. HVT-based vaccines cannot spread bird-to-bird in the field, so ensuring every chick or every hatching egg is properly vaccinated is the key to achieving a uniform protection. Watch our Mode of Action video to find out more.
Easy To Administer
INNOVAX-ND-IBD is the first-ever vaccine to provide immunization against classic and variant infectious bursal disease (IBD), Newcastle disease (ND), and Marek’s disease (MD) in one easy dose. Utilizing the herpesvirus of turkey (HVT) as a vector and genes of the IBD and ND viruses, the 3-in-1 formulation of INNOVAX-ND-IBD provides superior, life-long protection against all three diseases.
Breakthrough Innovation
Innovax-ND is a breakthrough in Newcastle disease control. This vaccine initiates immunity development during the bird’s first four weeks of life with minimal impact on its metabolism. Removing any significant metabolic reaction during the first several weeks of life while birds are growing and developing immunity has a positive effect on flock growth rates.
Better Protection, Healthier Flocks
INNNOVAX-ND-IBD is proven to provide better protection. Chickens vaccinated with INNOVAX-ND-IBD showed a lower bursal score and higher body and bursa weights when compared to a similar competitor vaccine after being challenged with one of three different IBDV field strains.2 Experience effective flock protection and performance with INNOVAX-ND-IBD.
References
- 1 Data on file, Merck Animal Health
- 2 Data on file, Merck Animal Health
Go To United States
Algeria
Argentina
Australia
Austria
Bahrain
Belgium (Dutch)
Brazil
Canada (English)
Chile
Colombia
Croatia
Czech Republic
Denmark
Ecuador
Egypt
Finland
France
Germany
Greece
Hungary
India
Indonesia
Iraq
Ireland
Israel
Italy
Japan
Jordan
Kuwait
Lebanon
Malaysia
Mexico
Morocco
Netherlands
New Zealand
Norway
Oman
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russian Federation
Saudi Arabia
South Africa
South Korea
Spain
Sweden
Switzerland (French)
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United Kingdom
Uruguay
Yemen
Global